NR4A1 and breast cancer: The primary aim of this study was to analyze changes in serum E2 levels using both routine and highly sensitive LC–MS/MS methods in postmenopausal women with early-stage hormone receptor-positive BC undergoing adjuvant letrozole therapy and concomitant vaginal estrogen therapy (Vagifem®) for symptomatic VVA.